Action Maxcyte - MXCT

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

265,00

Prix Achat

262,00

Prix Vente

268,00

Volume échangé

10 941

265,00 Fourchette du Jour 266,00

256,00 Plage de 52 semaines 405,00

Cap du marché

274,287M

Clôture Veille

264,00

Ouverture

266,00

Dernière Transaction

2000

265

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

34 057

Actions en circulation

103 504 571

Rendement du Dividende

Ratio Cours sur Bénéfices

-9,42

Bénéfice par action (BPA)

-0,37

Chiffre d'affairess

41,29M

Bénéfice net

-37,92M

Secteur

Biological Pds,ex Diagnstics

Industrie

Biological Pds,ex Diagnstics

Site Web

www.maxcyte.com

Siège social

Wilmington, Delaware, USA

Fondé

Maxcyte Inc est coté dans le secteur Biological Pds,ex Diagnstics de la London Stock Exchange avec le ticker MXCT. Le dernier cours de clôture d'Maxcyte était de 264,00p. Au cours de la dernière année, les actions de Maxcyte ont été négociées dans une fourchette de prix de 256,00p à 405,00p.

Maxcyte compte actuellement 103 504 571 actions en circulation. La capitalisation boursière d'Maxcyte est de £273,25 million. Maxcyte a un ratio cours/bénéfice (ratio PE) de -9.42.

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance ROCKVILLE, MD, March 11, 2025 — MaxCyte...

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

ROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading...

MaxCyte, Inc. Total Voting Rights

MaxCyte, Inc. 04 March 2025 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights ROCKVILLE, MD, 4 March 2025: MaxCyte Inc...

MaxCyte, Inc. Holding(s) in Company

MaxCyte, Inc. 19 February 2025 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the...

MaxCyte, Inc. Holding(s) in Company

MaxCyte, Inc. 14 February 2025 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the...

MaxCyte, Inc. Holding(s) in Company

MaxCyte, Inc. 13 February 2025 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the...

MaxCyte, Inc. Holding(s) in Company

MaxCyte, Inc. 13 February 2025 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the...

MaxCyte partners with TG Therapeutics on autoimmune cell therapy

MaxCyte Inc on Wednesday said it has signed a strategic platform licence with TG Therapeutics Inc to develop its auto ...

MaxCyte, Inc. Strategic Platform License with TG Therapeutics

MaxCyte, Inc. 12 February 2025 MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics...

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-3	-1.11940298507	268	277	262	22398	268.90315293	DE
4	-93	-25.9776536313	358	358	262	14902	295.65292914	DE
12	-75	-22.0588235294	340	405	262	34057	358.40532773	DE
26	-30	-10.1694915254	295	405	256	36404	314.5431407	DE
52	-50	-15.873015873	315	405	256	27035	323.16237815	DE
156	-165	-38.3720930233	430	645	172.5	35154	385.04082696	DE
260	115	76.6666666667	150	1230	122.5	79977	589.38651979	DE

MXCT - Frequently Asked Questions (FAQ)

What is the current Maxcyte share price?

The current share price of Maxcyte is 265,00p

How many Maxcyte shares are in issue?

Maxcyte has 103 504 571 shares in issue

What is the market cap of Maxcyte?

The market capitalisation of Maxcyte is GBP 273,25M

What is the 1 year trading range for Maxcyte share price?

Maxcyte has traded in the range of 256,00p to 405,00p during the past year

What is the PE ratio of Maxcyte?

The price to earnings ratio of Maxcyte is -9,42

What is the cash to sales ratio of Maxcyte?

The cash to sales ratio of Maxcyte is 8,65

What is the reporting currency for Maxcyte?

Maxcyte reports financial results in USD

What is the latest annual turnover for Maxcyte?

The latest annual turnover of Maxcyte is USD 41,29M

What is the latest annual profit for Maxcyte?

The latest annual profit of Maxcyte is USD -37,92M

What is the registered address of Maxcyte?

The registered address for Maxcyte is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Maxcyte website address?

The website address for Maxcyte is www.maxcyte.com

Which industry sector does Maxcyte operate in?

Maxcyte operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
GCMGcm Resources Plc	2,50p (36,99%)	19,2M
CRTCare Reit Plc	108,60p (33,58%)	85,61M
DELTDeltic Energy Plc	3,875p (19,23%)	3,08M
SOLISolid State Plc	202,50p (15,71%)	463,14k
PHEPowerhouse Energy Group Plc	0,75p (15,38%)	36,4M
SNGSynairgen Plc	1,20p (-39,85%)	6,45M
HEMOHemogenyx Pharmaceuticals Plc	195,00p (-36,17%)	712,91k
THRUThruvision Group Plc	1,60p (-28,89%)	425,77k
HVTHeavitree Brewery Plc	200,00p (-27,27%)	9,43k
ADFFacilities By Adf Plc	20,50p (-26,79%)	3,62M
VELAVela Technologies Plc	0,003p (7,14%)	2,23B
PREMPremier African Minerals Limited	0,0107p (-13,71%)	1,4B
UKOGUk Oil & Gas Plc	0,01p (-9,09%)	363,68M
CORCorpus Resources Plc	0,015p (3,45%)	304,93M
LLOYLloyds Banking Group Plc	67,16p (-2,92%)	197,24M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Maxcyte Inc (MXCT) Cours

Maxcyte Inc (MXCT)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Maxcyte Inc

MXCT Dernières nouvelles

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte, Inc. Total Voting Rights

MaxCyte, Inc. Holding(s) in Company

MaxCyte, Inc. Holding(s) in Company

MaxCyte, Inc. Holding(s) in Company

MaxCyte, Inc. Holding(s) in Company

MaxCyte partners with TG Therapeutics on autoimmune cell therapy

MaxCyte, Inc. Strategic Platform License with TG Therapeutics

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance

MaxCyte, Inc. Total Voting Rights

MaxCyte, Inc. Holding(s) in Company

MaxCyte, Inc. Holding(s) in Company

MaxCyte, Inc. Holding(s) in Company

MaxCyte, Inc. Holding(s) in Company

MaxCyte partners with TG Therapeutics on autoimmune cell therapy

MaxCyte, Inc. Strategic Platform License with TG Therapeutics

MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

MaxCyte, Inc. Notice of Results

MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference

MXCT - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités